Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

This study looks at a medicine called efgartigimod, which may help people with a condition called primary Sjögren's Syndrome (pSS). pSS is when the immune system mistakenly attacks healthy cells, causing dry mouth and eyes. Efgartigimod aims to reduce these attacks and improve symptoms. This study is "open-label," meaning both doctors and patients know what treatment is being given. Participants must have completed a previous study with efgartigimod and will receive 10 mg/kg of it for 48 weeks.

• 🕒 Study lasts 48 weeks with regular check-ups.
• 💊 Participants must have finished earlier efgartigimod studies.
• 🚫 Cannot join if planning surgery or if pregnant.

To join, you must be able to give consent and agree to use birth control if needed. If you have any serious health issues, you may not qualify. Safety is the focus, and this study will help understand how well efgartigimod works over a long period.